Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine (Nasdaq: PRME) announced management will participate in two investor conferences in October 2025. A fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference will be available on demand beginning October 14, 2025, with virtual 1x1 meetings on October 15, 2025. Allan Reine, M.D., will join a panel, “Genome Editing: Next Wave Technologies,” and host 1x1 meetings at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025 at 8:45 a.m. ET in New York.
Live audio webcasts and replays will be available under Events & Presentations on the company website, with replays accessible for 90 days after each event.
Prime Medicine (Nasdaq: PRME) ha annunciato che la direzione parteciperà a due conferenze per investitori nell'ottobre 2025. Una fireside chat durante la H.C. Wainwright Genetic Medicines Virtual Conference sarà disponibile on demand a partire dal 14 ottobre 2025, con incontri virtuali 1x1 il 15 ottobre 2025. Allan Reine, M.D., parteciperà a un panel, « Genome Editing: Next Wave Technologies, » e ospiterà incontri 1x1 alla Chardan’s 9th Annual Genetic Medicines Conference il 21 ottobre 2025 alle 8:45 a.m. ET a New York.
Le webcast audio dal vivo e le repliche saranno disponibili nella sezione Events & Presentations sul sito dell’azienda, con le repliche accessibili per 90 giorni dopo ogni evento.
Prime Medicine (Nasdaq: PRME) anunció que la dirección participará en dos conferencias para inversionistas en octubre de 2025. Una fireside chat en la H.C. Wainwright Genetic Medicines Virtual Conference estará disponible bajo demanda a partir del 14 de octubre de 2025, con reuniones virtuales 1x1 el 15 de octubre de 2025. Allan Reine, M.D., se unirá a un panel, “Genome Editing: Next Wave Technologies,” y organizará reuniones 1x1 en la Chardan’s 9th Annual Genetic Medicines Conference el 21 de octubre de 2025 a las 8:45 a.m. ET en Nueva York.
Las retransmisiones de audio en vivo y las repeticiones estarán disponibles en Events & Presentations en el sitio web de la empresa, con las repeticiones accesibles durante 90 días después de cada evento.
Prime Medicine (나스닥: PRME)는 경영진이 2025년 10월 두 개의 투자자 회의에 참여할 예정이라고 발표했습니다. H.C. Wainwright Genetic Medicines Virtual Conference에서의 파이어사이드 챗은 2025년 10월 14일부터 주문형으로 이용 가능하며, 가상 1x1 미팅은 2025년 10월 15일에 진행됩니다. Allan Reine, M.D.가 패널에 참여하고, “Genome Editing: Next Wave Technologies”를 주제로 하는 세션에서 1x1 미팅을 Chardan의 9번째 Annual Genetic Medicines Conference에서 2025년 10월 21일 동부 표준시 8:45에 주최합니다.
라이브 오디오 웨비나 및 재방송은 회사 웹사이트의 Events & Presentations에서 제공되며, 각 행사 후 90일 동안 재방송에 접근할 수 있습니다.
Prime Medicine (Nasdaq : PRME) a annoncé que la direction participera à deux conférences pour investisseurs en octobre 2025. Une entretiens au coin du feu lors de la H.C. Wainwright Genetic Medicines Virtual Conference sera disponible à la demande à partir du 14 octobre 2025, avec des réunions virtuelles 1x1 le 15 octobre 2025. Allan Reine, M.D., rejoindra un panel, « Genome Editing: Next Wave Technologies », et animera des réunions 1x1 à la Conférence annuelle des médicaments génétiques de Chardan n°9, le 21 octobre 2025 à 8h45 HNE à New York.
Les webcasts audio en direct et les rediffusions seront disponibles sous Events & Presentations sur le site de l’entreprise, les rediffusions étant accessibles pendant 90 jours après chaque événement.
Prime Medicine (Nasdaq: PRME) gab bekannt, dass das Management an zwei Investorenkonferenzen im Oktober 2025 teilnehmen wird. Ein Fireside-Chat bei der virtuellen H.C. Wainwright Genetic Medicines Virtual Conference wird ab dem 14. Oktober 2025 on demand verfügbar sein, mit virtuellen 1x1 Meetings am 15. Oktober 2025. Allan Reine, M.D., wird einem Panel beitreten, „Genome Editing: Next Wave Technologies“, und 1x1 Meetings bei Chardans neunter jährlicher Genetic Medicines Conference am 21. Oktober 2025 um 8:45 Uhr ET in New York leiten.
Live-Audio-Webcasts und Wiederholungen werden unter Events & Presentations auf der Unternehmenswebsite verfügbar sein, mit Wiederholungen, die 90 Tage nach jeder Veranstaltung zugänglich sind.
Prime Medicine (Nasdaq: PRME) أعلنت أن الإدارة ستشارك في مؤتمرين للمستثمرين في أكتوبر 2025. سيكون حديث بجلسة بجانب الموقد خلال مؤتمر H.C. Wainwright Genetic Medicines Virtual Conference متاحاً عند الطلب ابتداءً من 14 أكتوبر 2025، مع اجتماعات افتراضية 1x1 في 15 أكتوبر 2025. سينضم Allan Reine، د. م.، إلى لجنة نقاش، «Genome Editing: Next Wave Technologies»، وسيقوم باستضافة اجتماعات 1x1 في مؤتمر الشاردان التاسع السنوي للأدوية الجينية في 21 أكتوبر 2025 الساعة 8:45 صباحاً بتوقيت شرق الولايات المتحدة في نيويورك.
ستتوفر البثوث الصوتية المباشرة وإعادة البث تحت الأحداث والعروض على موقع الشركة، مع إمكانية الوصول إلى الإعادات لمدة 90 يوماً بعد كل حدث.
Prime Medicine (Nasdaq: PRME) 宣布管理层将参加两场2025年10月的投资者会议。H.C. Wainwright Genetic Medicines Virtual Conference 的 fireside chat 将从 2025年10月14日起按需提供，虚拟的 1x1 会谈将于 2025年10月15日 进行。Allan Reine, M.D. 将参加小组讨论“Genome Editing: Next Wave Technologies”，并在 Chardan 的第九届年度 Genetic Medicines Conference 上主持 1x1 会谈，时间为 2025年10月21日 8:45 a.m. ET，地点在纽约。
现场音频网络广播及回放将可在公司网站的 Events & Presentations 下获取，回放在每场活动结束后可访问 90 天。
- None.
- None.
CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences:
- H.C. Wainwright Genetic Medicines Virtual Conference 2025: Fireside chat will be available to view on demand beginning Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday, October 15, 2025.
- Chardan’s 9th Annual Genetic Medicines Conference: Allan Reine, M.D., will participate in a panel discussion, “Genome Editing: Next Wave Technologies,” and host 1x1 meetings on Tuesday, October 21, 2025, at 8:45 a.m. ET in New York, NY.
Live audio webcasts of the fireside chat and panel discussion will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. Replays of each webcast will be available on the Prime Medicine website for 90 days following the event.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
FAQ
When will Prime Medicine (PRME) make the H.C. Wainwright fireside chat available on demand?
What dates will Prime Medicine (PRME) management hold virtual 1x1 meetings at H.C. Wainwright?
When and where will Allan Reine, M.D., speak for Prime Medicine (PRME) at Chardan’s conference?
How can investors access Prime Medicine (PRME) webcasts and replays from the October 2025 conferences?
How long will Prime Medicine (PRME) replay recordings remain available after each event?
